Positive Results From Ustekinumab Biosimilar Phase I Trial and Infliximab Biosimilar Switching Studies
By EsqSocial Corporation 28/10/20
On October 20, 2020, NeuClone announced that it successfully completed its Phase I clinical trial of NeuLara, its proposed biosimilar of Stelara (ustekinumab). According to Neuclone, the Phase I clinical trial demonstrated similar clinical pharmacokinetics, and safety, immunogenicity and tolerability profiles of NeuLara compared to US- and EU-sourced Stelara....
By: Goodwin